HER2-Targeting Site-Specific Labelled 89Zr-Trastuzumab PET Imaging of Patients with Cancer

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516786-37-00

Acronym

AK-HER2-001

Enrollment

140

Registered

2024-11-05

Start date

2025-09-22

Completion date

Unknown

Last updated

2025-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastroesophageal adenocarcinomas or cancers with alterations in the ERBBR2 gene, Patients with breast cancer

None listed

Sex/Gender

All

Age

18 Years to No maximum

Denmark

None listed

Source: EU CTIS · Data processed: Feb 4, 2026